0001209191-19-056640.txt : 20191114
0001209191-19-056640.hdr.sgml : 20191114
20191114214453
ACCESSION NUMBER: 0001209191-19-056640
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191108
FILED AS OF DATE: 20191114
DATE AS OF CHANGE: 20191114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAHAM GINGER L
CENTRAL INDEX KEY: 0001192601
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 191222298
MAIL ADDRESS:
STREET 1: AMYLIN PHARMACEUTICALS, INC.
STREET 2: 885 ARAPAHOE AVENUE
CITY: BOULDER
STATE: CO
ZIP: 80302
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-08
1
0001131324
GENOMIC HEALTH INC
GHDX
0001192601
GRAHAM GINGER L
1108 NORTH LEMAY AVENUE
FORT COLLINS
CO
80524
1
0
0
0
Common Stock
2019-11-08
4
D
0
52349
D
955
I
Held by the GInger L. Graham Revocable Trust
Common Stock
2019-11-08
4
D
0
955
D
0
I
Held by the GInger L. Graham Revocable Trust
Director Stock Option (right to buy)
34.44
2019-11-08
4
D
0
8250
D
2013-06-08
2022-06-08
Common Stock
8250
0
D
Director Stock Option (right to buy)
35.87
2019-11-08
4
D
0
8250
D
2014-06-07
2023-06-07
Common Stock
8250
0
D
Director Stock Option (right to buy)
36.04
2019-11-08
4
D
0
1515
D
2014-06-07
2023-06-07
Common Stock
1515
0
D
Director Stock Option (right to buy)
27.75
2019-11-08
4
D
0
10000
D
2015-06-06
2024-06-06
Common Stock
10000
0
D
Director Stock Option (right to buy)
26.01
2019-11-08
4
D
0
10000
D
2016-06-12
2026-06-12
Common Stock
10000
0
D
Director Stock Option (right to buy)
26.18
2019-11-08
4
D
0
10000
D
2017-06-10
2026-06-10
Common Stock
10000
0
D
Director Stock Option (right to buy)
31.53
2019-11-08
4
D
0
10000
D
2018-06-16
2027-06-16
Common Stock
10000
0
D
Director Stock Option (right to buy)
51.72
2019-11-08
4
D
0
10000
D
2019-06-07
2028-06-07
Common Stock
10000
0
D
Director Stock Option (right to buy)
52.41
2019-11-08
4
D
0
6583
D
2020-06-14
2029-06-14
Common Stock
6583
0
D
Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,439,646 and 23,579 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $109,968 and 1,801 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $160,821 and 2,634 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
/s/ G. Bradley Cole, Attorney-in-fact
2019-11-14